Fixed vs random effects meta-analysis in rare event studies: The Rosiglitazone link with myocardial infarction and cardiac death

Statistics in Medicine

Volumn 26, Issue 24, 2007, Pages 4375-4385

  Shuster, Jonathan J ^a   Jones, Lynn S ^b   Salmon, Daniel A ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Midwest Clinical Research   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Low event rates; Meta analysis; Odds ratio; Random effects; Relative risk; Rosiglitazone

Indexed keywords

ROSIGLITAZONE;

ANALYTICAL ERROR; ARTICLE; CASE STUDY; CLINICAL TRIAL; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG SAFETY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MEDICAL RESEARCH; META ANALYSIS; NORMAL DISTRIBUTION; RISK ASSESSMENT; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 35148875463     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3060     Document Type: Article

References (23)

1. Nissen SE, Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 2007; 356(24):2457-2471.
2. Shuster JJ. Diagnostics for assumptions in moderate to large simple clinical trials: do they really help? Statistics in Medicine 2005; 24(16):2431-2438.
3. Follmann DA, Proschan MA. Valid inference in random effects meta-analysis. Biometrics 1999; 55(3):732-737.
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7(3):177-188.
5. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Statistics in Medicine 1995; 14(24):2685-2699.
6. Hartung J, Knapp GA. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Statistics in Medicine 2001; 20(24):3875-3889.
7. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Statistics in Medicine 2001; 20(6):825-840.
8. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Statistics in Medicine 2002; 21(11):1601-1623.
9. Burr D, Doss H. A Bayesian semiparametric model for random-effects meta-analysis. Journal of the American Statistical Association 2005; 100(1):242-251.
10. Kuhnert R, Bohning D. A comparison of three different methods for estimating relative risk in meta-analysis of clinical trials under unobserved heterogeneity. Statistics in Medicine 2007; 26(11):2277-2296.
11. Bohning D, Sarol J. Estimating risk difference in multicenter studies under baseline-risk heterogeneity. Biometrics 1990; 56(1):304-308.
12. Serfling RJ. Approximation Theorems in Mathematical Statistics. Wiley: New York, 1980; 118-125.
13. Cochran WG. Sampling Techniques. Wiley: New York, 1977; 153-157.
14. Shuster JJ. Fixing the number of events in large comparative trials with low event rates: a binomial approach. Controlled Clinical Trials 1993; 14(3):198-208.
15. Ellenberg SS. Safety concerns for new vaccine development. Pharmacoepidemiology and Drug Safety 2001; 10(5): 411-415.
16. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine 2002; 21(4):589-624.
17. Shuster JJ, Gieser PW. Meta-analysis and prospective meta-analysis in childhood leukemia clinical research. Journal of the European Society for Medical Oncology 1996; 7(10):1009-1014.
18. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. American Journal of Epidemiology 1999; 150(5):469-475.
19. Saul S. New York Times, 22 May 2007. New York Times Online.
20. Kahn SE, Haffner S, Heise MA et al. Glycemic durability of Rosiglitazone, Metformin, or Glyburide monotherapy. The New England Journal of Medicine 2006; 355(23):2477-2480.
21. Hallander P, Yu D, Chou H. Low dose Rosiglitazone in patients with insulin-requiring type 2 diabetes. Archives of Internal Medicine 2007; 167(12):1284-1290.
22. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosigilitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005; 48(9):1726-1735.
23. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Circulation 2003; 107(4):636-642.